Kose Bulent, Agca Alper
Department of Ophthalmology, Aritmi Osmangazi Hospital, Bursa, Turkey.
Department of Ophthalmology, Dünya Göz Hospital, Istanbul, Turkey.
Beyoglu Eye J. 2021 Sep 27;6(3):217-222. doi: 10.14744/bej.2021.82612. eCollection 2021.
The aim of this study was to compare the refractive results and safety of Artiflex (Ophtec BV, Groningen, Netherlands) and Eyecryl (BioTech Healthcare GmbH, Luzern, Switzerland) phakic intraocular lenses (pIOL).
The medical records of patients who underwent implantation of Artiflex or Eyecryl pIOL were retrospectively reviewed. Patients with a follow-up of 3 years were included in the study. Manifest refractive error, uncorrected and corrected visual acuity, intraocular pressure (IOP) and central endothelial cell density (ECD) data were evaluated preoperatively and at 1 and 3 years after surgery.
In all 79 eyes (Artiflex group: 35 eyes; Eyecryl group: 44 eyes) were included in the study. The preoperative spherical equivalent (SE) of manifest refractive error was -11.53±3.46 in the Artiflex group and -13.08±3.01 in the Eyecryl group. Three years after the operation, the efficacy index was 1.06±0.55 and 1.15±0.85 in the Artiflex and Eyecryl groups, respectively. The safety index was in 1.32±0.49 and 1.46±0.95 the Artiflex and Eyecryl groups, respectively. The SE refractive error, efficacy index, safety index UDVA, CDVA, IOP, and ECD were not significantly different between groups during follow-up.
Both the Artiflex and Eyecryl foldable pIOLs were found to be safe and effective up to 3 years after implantation. Prospective longitudinal studies are needed to assess and compare the rate of cataract formation.
本研究旨在比较Artiflex(荷兰格罗宁根Ophtec BV公司)和Eyecryl(瑞士卢塞恩BioTech Healthcare GmbH公司)有晶状体眼人工晶状体(pIOL)的屈光结果和安全性。
对接受Artiflex或Eyecryl pIOL植入术患者的病历进行回顾性分析。纳入随访3年的患者。评估术前、术后1年和3年的显验光不正、未矫正和矫正视力、眼压(IOP)及中央内皮细胞密度(ECD)数据。
本研究共纳入79只眼(Artiflex组:35只眼;Eyecryl组:44只眼)。Artiflex组术前显验光不正的等效球镜度(SE)为-11.53±3.46,Eyecryl组为-13.08±3.01。术后3年,Artiflex组和Eyecryl组的有效指数分别为1.06±0.55和1.15±0.85。Artiflex组和Eyecryl组的安全指数分别为1.32±0.49和1.46±0.95。随访期间,两组间的SE屈光不正、有效指数、安全指数、最佳矫正视力(UDVA)、矫正视力(CDVA)、眼压和ECD无显著差异。
Artiflex和Eyecryl可折叠pIOL在植入后3年内均安全有效。需要进行前瞻性纵向研究以评估和比较白内障形成率。